EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and …
GC Drosos, D Vedder, E Houben, L Boekel… - Annals of the …, 2022 - ard.bmj.com
Objective To develop recommendations for cardiovascular risk (CVR) management in gout,
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD) …
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD) …
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
C Dejaco, A Kerschbaumer, D Aletaha… - Annals of the …, 2024 - ard.bmj.com
Objectives To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and
polymyalgia rheumatica (PMR). Methods A systematic literature review was conducted to …
polymyalgia rheumatica (PMR). Methods A systematic literature review was conducted to …
Drug-induced hypertension
MC Foy, J Vaishnav, CJ Sperati - … and Metabolism Clinics, 2019 - endo.theclinics.com
From caffeine to state-of-the-art biological therapies, untoward side effects of
pharmaceuticals can result in considerable morbidity and expense to the health care …
pharmaceuticals can result in considerable morbidity and expense to the health care …
[PDF][PDF] One year in review 2019: vasculitis
S Monti, M Bond, M Felicetti, E Cavallaro… - Clin Exp …, 2019 - clinexprheumatol.org
Systemic vasculitis are disabling complex disorders potentially involving any organ and
system. Tremendous efforts have been made recently in this field with novel insights into …
system. Tremendous efforts have been made recently in this field with novel insights into …
[HTML][HTML] Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations
S Unizony, TJ McCulley, R Spiera, J Pei… - Arthritis Research & …, 2021 - Springer
Background Placebo-controlled clinical trials have demonstrated the efficacy of tocilizumab
(TCZ) for remission maintenance and glucocorticoid sparing in patients with giant cell …
(TCZ) for remission maintenance and glucocorticoid sparing in patients with giant cell …
Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study
S Unizony, MA Matza, A Jarvie, D O'Dea… - The Lancet …, 2023 - thelancet.com
Background Even after the approval of tocilizumab, substantial glucocorticoid exposure
(usually≥ 6 months) and toxicity continue to be important problems for patients with giant …
(usually≥ 6 months) and toxicity continue to be important problems for patients with giant …
[HTML][HTML] Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial
R Spiera, SH Unizony, M Bao, Y Luder, J Han… - Seminars in Arthritis and …, 2021 - Elsevier
Objective The randomized, placebo (PBO)-controlled GiACTA trial demonstrated the efficacy
and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA). The present study …
and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA). The present study …
The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial
Background Quantifying glucocorticoid toxicity is crucial to efforts to reduce it. The
Glucocorticoid Toxicity Index (GTI) measures toxicity effectively in clinical trials by calculating …
Glucocorticoid Toxicity Index (GTI) measures toxicity effectively in clinical trials by calculating …
[HTML][HTML] Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: A cohort study using routinely collected health data
Y Tanaka, S Tanaka, T Fukasawa, S Inokuchi… - Joint Bone Spine, 2024 - Elsevier
Objective We aimed to describe the following in patients with polymyalgia rheumatica
(PMR):(1) real-world glucocorticoid (GC) therapy,(2) improvement in inflammatory …
(PMR):(1) real-world glucocorticoid (GC) therapy,(2) improvement in inflammatory …
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial
TE Bolhuis, DE Marsman, AA den Broeder… - The Lancet …, 2023 - thelancet.com
Background Rituximab was effective for patients with polymyalgia rheumatica in the 21-
week BRIDGE-PMR randomised controlled trial. Here, we aimed to assess rates of …
week BRIDGE-PMR randomised controlled trial. Here, we aimed to assess rates of …